Guggenheim has upgraded Bristol-Myers Squibb Co (BMY) from Neutral to Buy as of December 11, 2025. This shift in rating reflects a more optimistic outlook on the company’s prospects, potentially indicating improved fundamentals or enhanced confidence in its strategic direction.
Bristol-Myers Squibb, headquartered in Princeton, New Jersey, is a leading player in the pharmaceuticals industry. The company focuses on the discovery, development, and delivery of transformative medicines for patients battling serious diseases, including oncology, hematology, and immunology. Its robust portfolio features key products like Opdivo (nivolumab) and Yervoy (ipilimumab), among others.
Currently, BMY trades at $52.45, with a market capitalization of $104.1 billion. The company has a P/E ratio of 17.24 and an impressive dividend yield of 492.1%. Looking ahead, analysts expect the company to report earnings of $1.53 per share on October 29, 2026, with revenue estimates of $11.4 billion.
Analyst ratings, like this upgrade, serve as professional opinions based on extensive research and financial modeling. They can provide valuable insights but should be considered alongside other factors such as company fundamentals and market trends. It's important to remember that analyst views can evolve as new information becomes available, and different analysts may offer varying perspectives on the same company.